Levels of markers of coagulation and fibrinolysis systems in patients with pulmonary tuberculosis with concomitant diabetes mellitus after COVID-19
https://doi.org/10.29413/ABS.2024-9.3.22
Abstract
Background. It is known that COVID-19 can be followed by a shift in the hemostatic system towards hypercoagulation, which is more pronounced in the presence of diabetes mellitus (DM). Tuberculosis process is often accompanied with hypercoagulation syndrome. Of great interest is the study of the state of hemostatic systems in patients with pulmonary tuberculosis (TB) with concomitant DM who have had COVID-19.
The aim. To study the relationship between the state of the hemostatic and fibrinolysis systems and moderate and severe COVID-19 in patients with pulmonary tuberculosis and diabetes mellitus.
Methods. 32 patients with TB and DM were divided into two groups. Group 1 included 16 patients with TB and DM who have previously had COVID-19 (TB-DM-COVID). Group 2 included 16 patients with TB and DM who did not have COVID-19 (TB-DM).
Results. It was found that TB-DM-COVID patients were more likely to develop a hypercoagulable shift compared to TB-DM patients. This was evidenced by a more frequent shortening of such indicator as activated partial thromboplastin time (43.7 % and 25.0 % of cases, respectively; χ2 = 7.22; p = 0.01), an increase in fibrinogen levels (43.7 % and 25.0%, respectively; χ2 = 7.22; p = 0.01) and D-dimer (43.7 % and 18.7 %, respectively; χ2 = 14.74; p = 0.0001). These changes were closely associated with the systemic inflammatory response, as strong and positive correlations were found between fibrinogen and C-reactive protein levels (r = 0.420; p = 0.01), and erythrocyte sedimentation rate (r = 0.433; p = 0.01) in TB-DM-COVID patients.
Conclusion. In patients with pulmonary tuberculosis and diabetes mellitus after moderate and severe COVID-19, compared to patients who have not had COV ID-19, a hypercoagulable shift associated with the development of more pronounced systemic inflammation develops more often.
About the Authors
R. Yu. Abdullaev
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Rizvan Yu. Abdullayev – Dr. Sc. (Med.), Professor, Head of the Department of Pathomorphology, Cell Biology and Biochemistry
Yauzskaya alley 2, Moscow 107564
O. G. Komissarova
Central Tuberculosis Research Institute; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Oksana G. Komissarova – Dr. Sc. (Med.), Deputy Director for Medical and Scientific Work; Professor at the Department of Phthisiology, Faculty of Medicine
Yauzskaya alley 2, Moscow 107564
Ostrovitianova str. 1, Moscow 117321
V. A. Shorokhova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Violetta A. Shorokhova – Cand. Sc. (Med.), Junior Research Officer at the Department of Pathomorphology, Cell Biology and Biochemistry
Yauzskaya alley 2, Moscow 107564
References
1. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. URL: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 date of access: 26.02.2024
2. On the state of sanitary and epidemiological well-being of the population of the Russian Federation in 2022: State report of Rospotrebnadzor. Moscow; 2023. (In Russ.) URL: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=25076&ysclid=lt6r30hh ia904823086 дата доступа: 29.02.2024
3. Savintseva EV, Isaeva PV, Nizamova GF. Tuberculosis and COVID-19: Medical and social aspects. Tuberculosis and Lung Diseases. 2022; 100(3): 13-17. (In Russ.) doi: 10.21292/2075-1230-2022-100-3-13-17
4. Aggarwal AN, Agarwal R, Dhooria S, Prasad KT, Sehgal IS, Muthu V. Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and metaanalysis. PLoS One. 2021; 16(10): e0259006. doi: 10.1371/journal.pone.0259006
5. Dedov II, Shestakova MV, Mayorov AYu. Algorithms for specialized medical care for patients with diabetes. Moscow; 2023. (In Russ.)
6. International Diabetes Federation. IDF Diabetes Atlas; 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. URL: https://www.diabetesatlas.org date of access: 12.07.2023
7. Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: A systematic review and meta-analysis of data from 2,3 million patients with tuberculosis. Lancet Glob Health. 2019; 7(4): e448-e460. doi: 10.1016/S2214-109X(18)30487-X
8. Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, et al. Bi-directional screening for tuberculosis and diabetes: A systematic review. Trop Med Int Health. 2010; 15(11): 1300-1314. doi: 10.1111/j.1365-3156.2010.02632.x
9. Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One. 2017; 12(4): 1-25. doi: 10.1371/journal.pone.0175925
10. World Health Organization. Weekly epidemiological update on COVID-19. 6 July 2023; Edition 150. URL: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2023 date of access: 12.07.2023
11. Lippi G, Henry BM, Favresse J, Plebani M. Addressing standardized definitions of post-COVID and long-COVID. Clin Chem Lab Med. 2023; 61(8): 1361-1362. doi: 10.1515/cclm-2023-0390
12. Komissarova OG, Abdullaev RYu, Shorokhova VA. Features of pulmonary tuberculosis in patients who have had an infection caused by SARS-CoV-2. Modern Problems of Science and Education. 2023; (4). (In Russ.) URL: https://scienceeducation.ru/article/view?id=32737 дата доступа: 27.02.2024
13. Abdullaev RYu, Komissarova OG, Krasnikova EV, Bagirov MA, Ergeshov AE. Hemostasis and fibrinolysis parameters in pulmonary TB patients after COVID-19 infection before and after surgery. CTRI Bulletin. 2022; (2): 18-24. (In Russ.) doi: 10.7868/S2587667822020029
14. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844-847. doi: 10.1111/jth.14768
15. Abdullaev RYu, Komissarova OG, Rybka MM, Berezovskiy YuS, Grekov EM, Semenova LA. Clinical and laboratory manifestations and pathological anatomical picture of a severe course of a new coronavirus infection COVID-19 with a fatal outcome. Infectious Diseases: News, Opinions, Training. 2022; 11(4): 30-37. (In Russ.) doi: 10.33029/2305-3496-2022-11-4-30-37
16. Abdullaev RYu, Komissarova OG, Konyaeva OO, Romanov VV. Changes in the parameters of hemostasis and fibrinolysis systems in patients with pulmonary tuberculosis with concomitant diabetes mellitus. Tuberculosis and Socially Significant Diseases. 2021; (1): 60. (In Russ.)
17. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection. 2022. (In Russ.) URL: https://minzdrav.gov.ru/ministry/med_covid19 дата доступа: 12.07.2023
Review
For citations:
Abdullaev R.Yu., Komissarova O.G., Shorokhova V.A. Levels of markers of coagulation and fibrinolysis systems in patients with pulmonary tuberculosis with concomitant diabetes mellitus after COVID-19. Acta Biomedica Scientifica. 2024;9(3):222-229. (In Russ.) https://doi.org/10.29413/ABS.2024-9.3.22
Views:
336
.png)
Email this article 
